PROM1 and neoplasm: Nonetheless, larger prospective study with serial CD133 mRNA levels performed at diagnosis, pre- and post-treatment and at time of progression along with circulating tumor cells enumerations are needed to assess the value of CD133 mRNA as a surrogate marker.